Drug Modulation of Water鈥揌eme Interactions in Low-Spin P450 Complexes of CYP2C9d and CYP125A1

详细信息    查看全文

• 作者：Kip P. Conner ; Alex A. Cruce ; Matthew D. Krzyaniak ; Alina M. Schimpf ; Daniel J. Frank ; Paul Ortiz de Montellano ; William M. Atkins ; Michael K. Bowman
• 刊名：Biochemistry
• 出版年：2015
• 出版时间：February 10, 2015
• 年：2015
• 卷：54
• 期：5
• 页码：1198-1207
• 全文大小：474K
• ISSN：1520-4995

文摘

Azoles and pyridines are commonly incorporated into small molecule inhibitor scaffolds that target cytochromes P450 (CYPs) as a strategy to increase drug binding affinity, impart isoform-dependent selectivity, and improve metabolic stability. Optical absorbance spectra of the CYP鈥搃nhibitor complex are widely used to infer whether these inhibitors are ligated directly to the heme iron as catalytically inert, low-spin (type II) complexes. Here, we show that the low-spin complex between a drug-metabolizing CYP2C9 variant and 4-(3-phenylpropyl)-1H-1,2,3-triazole (PPT) retains an axial water ligand despite exhibiting elements of 鈥渃lassic鈥?type II optical behavior. Hydrogens of the axial water ligand are observed by pulsed electron paramagnetic resonance (EPR) spectroscopy for both inhibitor-free and inhibitor-bound species and show that inhibitor binding does not displace the axial water. A ¹⁵N label incorporated into PPT is 0.444 nm from the heme iron, showing that PPT is also in the active site. The reverse type I inhibitor, LP10, of CYP125A1 from Mycobacterium tuberculosis, known from X-ray crystal structures to form a low-spin water-bridged complex, is found by EPR and by visible and near-infrared magnetic circular dichroism spectroscopy to retain the axial water ligand in the complex in solution.